Amgen Inc
(BUE:AMGN)
ARS
10425
-25 (-0.24%)
Market Cap: 153.50 Til
Enterprise Value: 205.37 Til
PE Ratio: 36.22
PB Ratio: 20.20
GF Score: 57/100 Amgen Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 27, 2021 / 06:00PM GMT
Release Date Price:
ARS4101.5
(+4.63%)
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research
Hey, everybody. It's Alethia Young here. I cover large-cap, small, mid-cap biotech here at Cantor. Very happy to have Amgen with us this afternoon. We have Peter Griffith, who's the Executive Vice President and CFO. We have Susan Sweeney, who is SVP of Global Marketing, Access and Capabilities. We have Arvind Sood, who needs no introduction but VP of IR; and we have Omari Wise, who's the Executive Director in the IR team as well.
So we'll be doing a fireside chat for the next 30 minutes, and I'm just going to dive right on in.
Questions & Answers
Alethia Rene Young;Susan Sweeney
Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research;
And so maybe this one is for Susan, perhaps. Just talk a little bit about how you collaborate with the commercial team to drive solutions that improve outcomes for patients and customers overall.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot